Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

520
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
520
Cancer Survival Analysis01:21

Cancer Survival Analysis

819
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
819
Hazard Ratio01:12

Hazard Ratio

687
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
687

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Variation in the time to treatment for stage III and IV non-small cell lung cancer patients for hospitals in the Netherlands.

Lung cancer (Amsterdam, Netherlands)·2019
Same author

A scoping review of metamodeling applications and opportunities for advanced health economic analyses.

Expert review of pharmacoeconomics & outcomes research·2018
Same author

Early Stage Cost-Effectiveness Analysis of a Brca1-Like Test to Detect Triple Negative Breast Cancers Responsive to High Dose Alkylating Chemotherapy.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Comparison of the Valuation of Treatment Alternatives in Parkinson's Disease with Best-Worst Scaling, Time Trade-off and Visual Analogue Scales.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Combining Headroom and Return on Investment Analysis To Rank Potential Commercial Value of Six Medical Devices in Development.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

A Systematic Review To Identify the Use of Preference Elicitation Methods in Health Care Decision Making.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016

Related Experiment Video

Updated: Mar 20, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Primary Treatments for Intermediate-Risk Prostate Cancer: a Cost-Effectiveness and Value-of-Information Analysis

M Piena1, M J IJzerman2, L M G Steuten3

  • 1PANAXEA bv, Enschede, The Netherlands.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|May 21, 2016
PubMed
Summary

No abstract available in PubMed .

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.0K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

9.8K

Related Experiment Videos

Last Updated: Mar 20, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.0K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

9.8K